Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Colorcon
McKinsey
Harvard Business School
Merck

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Litigation Details for Sanofi-Aventis U.S. LLC v. Eli Lilly and Company (D. Del. 2014)

See Plans and Pricing

« Back to Dashboard

Sanofi-Aventis U.S. LLC v. Eli Lilly and Company (D. Del. 2014)

Docket   Start Trial Date Filed 2014-01-30
Court District Court, D. Delaware Date Terminated 2015-09-28
Cause 35:271 Patent Infringement Assigned To Richard Gibson Andrews
Jury Demand None Referred To Judge Mary Pat Thynge
Parties DAVID M. FRISCHKORN; ELI LILLY AND COMPANY; SANOFI-AVENTIS DEUTSCHLAND GMBH; SANOFI-AVENTIS U.S. LLC; THOMAS E. WETTERMANN
Patents 5,656,722; 7,476,652; 7,713,930; 7,918,833; 8,512,297; 8,556,864; 8,603,044; 8,679,069
Attorneys Andrew Colin Mayo; Anne Champion; Benjamin J. Schladweiler; Brian E. Farnan; Bruce M. Wexler; David M. Conca; Gerald J. Flattmann , Jr.; Jessica L. Greenbaum; Joseph Evall; Kevin P. Broughel; Lauren E. Maguire; Nicholas A. Tymoczko; R. Scott Roe; Samantha N. Hong; Steven J. Balick; Steven L. Park; Tiffany Geyer Lydon; Tracey B. Davies; Young J. Park
Firms Ross Aronstam & Moritz LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Sanofi-Aventis U.S. LLC v. Eli Lilly and Company
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Sanofi-Aventis U.S. LLC v. Eli Lilly and Company (D. Del. 2014)

Date Filed Document No. Description Snippet Link To Document
2014-03-17 13 seven patents in the Orange Book against Lantus® and Lantus® SoloSTAR®. U.S. Patent No. 5,656,722 (“’722…’044 patent”), 8,556,864 (“’864 patent”), 8,512,297 (“’297 patent”), and 7,918,833 (“’833 patent”) relate…“’930 patent”) and 7,476,652 (“’652 patent”) relate to the Lantus® formulation; and U.S. Patent Nos. …’722 patent”) relates to the active ingredient in Lantus®, insulin glargine; U.S. Patent Nos. 7,713,930…seven Orange Book-listed patents—the ’930, ’652, ’044, ’864, ’297, and ’833 patents—are invalid, unenforceable External link to document
2015-01-20 192 found in U.S. Patent Nos. 7,476,652 and 7,713,930 (collectively, the "Formulation Patents") and…quot; ('864 patent: claims 2, 3; '044 patent: claims 1, 3, 11, 13; '069 patent: claim 1) …#39;864 patent into the '044 and '069 patents. (D.1. 183 & 184). The '864 patent defines…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which … Except for the claims, the '044 patent and '069 patent are almost identical. For the sake of External link to document
2015-09-28 279 '044 Patent); 7,476,652 (the '652 Patent); 7,713,930 (the '930 Patent); and 8,… the asserted patents (i.e., U.S. Patent Nos. 8,556,864 (the '864 Patent); 8,603,044 (…8,679,069 (the '069 Patent)). 2. This Consent Judgment constitutes a "consent decree… 28 September 2015 1:14-cv-00113 830 Patent None District Court, D. Delaware External link to document
2014-01-30 4 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,556,864 B2; 8,603,044 B2; 7,476,652 B2; 7,713,930… 28 September 2015 1:14-cv-00113 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
AstraZeneca
Medtronic
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.